Previous studies involving recombinant dog proteins have shown that the clustering genetic variation of the nicotinic acetylcholine receptor subunit (CHRNA5-CHRNA3-CHRNB4) on chromosome 15 has a strong association with smoking and the risk of smoking-related disease. CHRNA5-CHRNA3-CHRNB4 includes chronic obstructive pulmonary disease (COPD), peripheral arterial disease and lung cancer.
As multivariate label of CHRNA5-CHRNA3-CHRNB3 cluster, whether rs1051730 (C/T) is associated with changes in incidence and morbidity of smoking-related diseases? In this regard, we analyzed a population-based prospective cohort study (Malmö diet and cancer study).
At baseline, participants were divided into three groups: current smokers (n = 6951), former smokers (n = 8426), and never smokers (n = 9417). They used Cox proportional hazards model to assess the association of rs1051730 and first-time COPD, smoking-related cancers, other cancers and cardiovascular diseases. They also followed the association between rs1051730 and the overall mortality risk from these diseases in the next nearly 14 years.
Data shows that among current smokers, the first COPD, smoking-related cancer, other cancers and cardiovascular diseases respectively showed 480 cases, 852 cases, 810 cases and 1022 cases. There were a total of 1,508 deaths, among which cardiovascular disease, respiratory disease and cancer were respectively 500, 102 and 677 deaths.
The analysis showed that with the increase in the number of T alleles, the overall mortality, COPD and incidence of tobacco-related cancers increased. The association remained after adjustment for smoking. But for people who never smoked, they did not show this connection.
Our data showed that the genetic variation of the CHRNA5-CHRNA3-CHRNB3 cluster is associated with the increase of mortality of smokers, COPD and incidence of tobacco-related cancers. Flarebio provides good-quality recombinant proteins like recombinant ITGB2 at competitive prices.
没有评论:
发表评论